Reach Us +441234923305


Interview | Ioan MagyarnbspClinical Pharmacology and Bi
ISSN: 2167-065X

Clinical Pharmacology & Biopharmaceutics
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Ioan Magyar
Ioan Magyar

Ioan Magyar
Associate Professor
Department of Pharmacology
University of Oradea
Read Interview session with Ioan Magyar



Ioan Magyar is 51 years old and he has completed his PhD at the age of 41 years from University of Oradea. A several postdoctoral studies organized by British Pharmacological Society were carried out in London, U.K. These workshops include Enzymes as Drug Targets (2011), Drug Discovery (2012) and Clinical Discovery (2012). He’s Assoc Professor of Basic & Clinical Pharmacology at Faculty of Medicine & Pharmacy, University of Oradea, Romania. He is head of Department of Pharmacology, and he is also involved in clinical medicine activity (emergency medicine). He has published about 60 papers (some of them in Romanian, and others in English). The main topics of his scientific activity belongs to Clinical Pharmacology & Pharmacovigilance fields.

Research Interest

Drug Discovery, Drug Targets

1. How many years have you been practicing and/or performing research?
I' m involved in clinical practice 23 years ago and 16 years in research activity, respectively.

2. What is the research topic you are working on now?
The main field of my interest research activity is clinical pharmacology & pharmacovigilance fields; the current working topic is a toxicological one.

3. What makes an article top quality?
In my opinion, the top quality of an article is assured by accuracy and concise formulation, the proper statistical methods, and relevance for clinical practice and healthcare process.

4. What are the qualities you look for in an article?
The main quality which I try to look for it is the relevance for improving of both healthcare and quality of life for patients.

5. Do you have any research funding (NIH or other national funding) now?
No, I haven't any research funding or grant.

6. When did you become an editor of OMICS Journal?
At the beginning of the current year.

7. What is your greatest career accomplishment?
Associate Professor of Pharmacology (Basic & Clinical) position.

8. How does the research published percolate through to practitioners?
I think that a good quality of published research could be a warranty for a better clinical practice (and practitioners of course).

9. What is the purpose of serving as an editor?
The main my purpose is to make a strong relationship between the basic scientific process and clinical research activity.

10. Do you have any patents?
No, I haven't.

11. Have you contributed any editorials or papers (any types) to OMICS Journals in the past two years?
Yes, an article published in Experimental and Clinical Pharmacology Journal, November 2013.

12. Do you plan to contribute any editorials or papers to OMICS Journals in the next year?
Yes, of course, but we have some limits because the fee is very high regard to our income.

13. Do you have any trouble with OMICS Journals in the past?
No, except level of fee, which I mentioned previously.

14. Would you recommend OMICS to your friends or colleagues?
The OMICS journals were recommended, immediately after my attendance of Clinical Pharmacy & Dispensing, San Antonio, 2013.

15. How do you differentiate Journal, Clinical Pharmacology & Biopharmaceutics with other journals in the field?
I think is a very serious Journal and it can accomplish the proper link between clinical pharmacology and basic pharmacology; the Journal also can create o good relationship between clinical pharmacists and pharmacologists (or physicians).